Patents by Inventor Steffen Schlehuber
Steffen Schlehuber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10785973Abstract: The present invention relates to an aqueous pesticide microemulsion formulation including (a) at least one organic pesticide compound P, which is sparingly soluble in water and which is present in the formulation in dissolved form; (b) at least one organic solvent LM1 selected from C1-C4-alkyl lactates; (c) at least one organic solvent LM2 selected from C5-C12-alkyl lactates; (d) at least one organic solvent LM3 selected from N—(C4-C12 alkyl)pyrrolidones; (e) at least one surfactant S selected from anionic surfactants and non-ionic surfactants and mixtures thereof; and (f) water.Type: GrantFiled: September 2, 2015Date of Patent: September 29, 2020Assignee: BASF SEInventors: Claude Taranta, Steffen Schlehuber, Sarah Thompson, Wolfgang Meier, Jochen Schreieck, Helmut Mueller, Paulo Cesar Queiroz
-
Publication number: 20190159455Abstract: The present invention relates to the use of a pesticidal mixtures comprising as active components tioxazafen for protecting plants, the plant propagation material thereof, or soil or water, in which the plants are growing, against the attack or infestation by invertebrate pests and/or phytopathogenic harmful fungi. Furthermore, the present invention relates to a seed treatment composition comprising at least one of the pesticidal mixtures and to seeds comprising at least one of the pesticidal mixtures or the seed treatment composition thereof. Moreover, the present invention relates to a method for controlling invertebrate pests and/or phytopathogenic harmful fungi on plants comprising contacting the plant or the plant propagation material; the pest or its food supply, habitat or breeding ground; and/or the fungi or their habitat, with an effective amount of the pesticidal mixtures or the seed treatment compositions thereof.Type: ApplicationFiled: March 31, 2017Publication date: May 30, 2019Inventors: Eric BAS, Todd EDGINGTON, Ronald WILHELM, Steffen SCHLEHUBER, Florent MAZUIR
-
Publication number: 20190015477Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: July 10, 2018Publication date: January 17, 2019Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 10046027Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: December 28, 2015Date of Patent: August 14, 2018Assignee: PIERIS PHARMACEUTICALS GMBHInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Publication number: 20170280710Abstract: The present invention relates to an aqueous pesticide microemulsion formulation including (a) at least one organic pesticide compound P, which is sparingly soluble in water and which is present in the formulation in dissolved form; (b) at least one organic solvent LM1 selected from C1-C4-alkyl lactates; (c) at least one organic solvent LM2 selected from C5-C12-alkyl lactates; (d) at least one organic solvent LM3 selected from N—(C4-C12 alkyl)pyrrolidones; (e) at least one surfactant S selected from anionic surfactants and non-ionic surfactants and mixtures thereof; and (f) water.Type: ApplicationFiled: September 2, 2015Publication date: October 5, 2017Inventors: Claude Taranta, Steffen Schlehuber, Sarah Thompson, Wolfgang Meier, Jochen Schreieck, Helmut Mueller, Paulo Cesar Queiroz
-
Publication number: 20160256525Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: December 28, 2015Publication date: September 8, 2016Applicant: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 9221887Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: September 14, 2012Date of Patent: December 29, 2015Assignee: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Publication number: 20130017996Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 8313924Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: August 1, 2007Date of Patent: November 20, 2012Assignee: Pieris AGInventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 7892827Abstract: The present invention relates to a compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid.Type: GrantFiled: November 25, 2005Date of Patent: February 22, 2011Assignee: Pieris AGInventors: Gabriele Matschiner, Andreas Hohlbaum, Steffen Schlehuber, Martin Pöhlchen, Arne Skerra
-
Patent number: 7893208Abstract: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: GrantFiled: August 19, 2009Date of Patent: February 22, 2011Assignee: Pieris AGInventors: Arne Skerra, Steffen Schlehuber
-
Patent number: 7691970Abstract: The present invention relates to novel muteins derived from a bilin-binding protein (BBP) that binds a given target, for example a macromolecular target, with detectable affinity. In particular, the invention relates to a mutein of the bilin-binding protein of Pieris brassicae. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: GrantFiled: August 25, 2003Date of Patent: April 6, 2010Assignee: Pieris AGInventors: Arne Skerra, Steffen Schlehuber
-
Publication number: 20090325875Abstract: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: ApplicationFiled: August 19, 2009Publication date: December 31, 2009Inventors: Arne Skerra, Steffen Schlehuber
-
Publication number: 20090305982Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: August 1, 2007Publication date: December 10, 2009Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Patent number: 7585940Abstract: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: GrantFiled: August 24, 2004Date of Patent: September 8, 2009Assignee: Pieris AGInventors: Arne Skerra, Steffen Schlehuber
-
Publication number: 20090042785Abstract: The present invention relates to a compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid.Type: ApplicationFiled: November 25, 2005Publication date: February 12, 2009Inventors: Gabriele Matschiner, Andreas Hohlbaum, Steffen Schlehuber, Martin Pohlchen, Arne Skerra
-
Publication number: 20070224633Abstract: The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: ApplicationFiled: August 24, 2004Publication date: September 27, 2007Applicant: PIERIS AGInventors: Arne Skerra, Steffen Schlehuber
-
Patent number: 7252998Abstract: Disclosed is a method for generating a mutein of a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat ?2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having detectable affinity to a given target. The method comprises the step of subjecting the protein to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in one or more mutein(s) of the protein. Also disclosed are muteins obtainable by this method.Type: GrantFiled: September 18, 2002Date of Patent: August 7, 2007Assignee: Pieris AGInventors: Arne Skerra, Steffen Schlehuber
-
Publication number: 20070148201Abstract: The present invention relates to novel muteins derived from a bilin-binding protein (BBP) that binds a given target, for example a macromolecular target, with detectable affinity. In particular, the invention relates to a mutein of the bilin-binding protein of Pieris brassicae. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.Type: ApplicationFiled: August 25, 2003Publication date: June 28, 2007Inventors: Arne Skerra, Steffen Schlehuber
-
Publication number: 20060088908Abstract: Disclosed is a method for generating a mutein of a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hN-GAL), rat ?2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having detectable affinity to a given target. The method comprises the step of subjecting the protein to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in one or more mutein(s) of the protein. Also disclosed are muteins obtainable by this method.Type: ApplicationFiled: September 18, 2002Publication date: April 27, 2006Inventors: Arne Skerra, Steffen Schlehuber